NTRK2 and depressive symptom measurement: BDNF and TrkB have been shown to regulate development of depression-like phenotypes and anxiety-related behaviors [14], [40], [41], [42], depicting TrkB as a promising target for the development of new therapeutic compounds [13], [43].